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Objective:  Metabolic  acidosis  is  associated  with  high  mortality.  Despite  theoretical  benefits  of
sodium-bicarbonate  (SB),  current  evidence  remains  controversial.  We  investigated  SB-related
effects on  outcomes  in  ICU  patients  with  metabolic  acidosis.
Design:  Retrospective  analysis.
Setting:  Academic  medical  center.
Patients  or  participants:  971  ICU  patients  with  metabolic  acidosis  defined  as  arterial  pH  <  7.3
and CO2 <  45  mmHg  treated  between  2012  and  2016.  A  propensity  score  (PS)  was  estimated  using
logistic regression.  Patients  were  matched  in  pairs  using  the  PS.
Interventions:  441  patients  were  treated  with  SB  8.4%  (SB-group)  and  n  =  530  patients  were  not
(control  group).
Main  variables  of  interest:  Primary  outcome  was  all-cause  mortality  at  ICU-discharge.  Average
Treatment  Effect  (ATE),  Average  Treatment  effect  in  Treated  (ATT),  and  estimated  relative
survival  effects  at  20  days  were  computed.
Results:  In  the  full  cohort,  we  observed  considerable  differences  in  pH,  base  excess,  additional
acidosis-related  indices,  and  ICU  mortality  (controls  31%  vs.  SB-group  56%,  p  <  .001)  at  baseline
between the  two  groups.  After  PS-matching  (n  =  174  in  each  group),  no  significant  difference  in (controls  32%  vs.  SB-group  41%;  p  =  .07).  Odds  ratios  (OR)  for  ATE
tion  with  ICU  mortality  (OR  ATE:  1.08,  95%-CI  0.99--1.17;  p  =  .08;
1.2;  p  =  .09).  Hazard  ratios  at  20-days  (multivariable  HR,  matched
I  0.86--1.56,  p  =  .33)  showed  similar  survival  in  the  two  study  groups.ICU mortality  was  observed
and ATT  showed  no  associa
OR ATT  1.09;  95%-CI  0.99--
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Conclusions:  We  did  not  observe  effects  of  SB  infusion  on  all-cause  mortality  in  critically  ill
patients with  metabolic  acidosis.
©  2021  The  Author(s).  Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Efectos  de  la  infusión  de  bicarbonato  de  sodio  sobre  la  mortalidad  en  pacientes  de
UCI  médico-quirúrgica  con  acidosis  metabólica:  un  análisis  de  puntuación  de
propensión  en  un  solo  Centro
Resumen
Objetivo:  La  acidosis  metabólica  se  asocia  con  una  alta  mortalidad.  A  pesar  de  los  beneficios
teóricos del  bicarbonato  de  sodio  (BS),  la  evidencia  actual  sigue  siendo  controvertida.  Investig-
amos los  efectos  relacionados  con  el  BS  sobre  los  resultados  en  pacientes  de  la  UCI  con  acidosis
metabólica.
Diseño: Análisis  retrospectivo.
Ámbito:  Centro  médico  académico.
Pacientes  o  participantes:  Se  incluyeron  971  pacientes  de  la  Unidad  de  Cuidados  Intensivos
(UCI) con  acidosis  metabólica  (pH  <  7,3,  CO2  <  45  mmHg)  tratados  entre  2012  y  2016.  Se  calculó
una puntuación  de  propensión  (PS)  mediante  regresión  logística.  Los  pacientes  se  emparejaron
utilizando el  PS.
Variables  de  interés  principales: Intervenciones;  441  pacientes  fueron  tratados  con  BS  8,4%
(grupo BS)  y  n  =  530  pacientes  no  (grupo  control).
Resultados:  El  resultado  primario  fue  la  mortalidad  por  todas  las  causas  al  alta  de  la  UCI.  Se
calcularon  el  efecto  promedio  del  tratamiento  (ATE),  el  efecto  promedio  del  tratamiento  en
los tratados  (ATT)  y  los  efectos  de  supervivencia  relativa  estimados  a  los  20  días.  En  la  cohorte
completa  se  observaron  diferencias  considerables  en  el  pH,  el  exceso  de  bases  y  la  mortalidad
en la  UCI  (control  31%  vs.  grupo  BS  56%,  p  <  0,001)  al  inicio  del  estudio  entre  los  grupos.  Después
del emparejamiento  de  PS  (n  =  174  en  cada  grupo),  no  se  observaron  diferencias  significativas
en la  mortalidad  en  la  UCI  (control  32%  vs.  grupo  BS  41%;  p  =  0,07).  Los  odds  ratios  (OR)  para
ATE y  ATT  no  mostraron  asociación  con  la  mortalidad  en  la  UCI  (OR  ATE:  1,08,  IC  95%;  0,99-1,17;
p =  0,08;  OR  ATT  1,09;  IC  95%;  0,99-1,2;  p  =  0,09).  Los  cocientes  de  riesgo  a  los  20  días  (HR
multivariable,  muestra  emparejada  n  =  348:  1,16,  IC  95%;  0,86-1,56,  p  =  0,33)  mostraron  una
supervivencia  comparable.
Conclusiones:  No  observamos  efectos  de  la  infusión  de  BS  sobre  la  mortalidad  por  todas  las
causas en  pacientes  con  acidosis  metabólica.
© 2021  El  Autor(s).  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un  art́ıculo  Open  Access  bajo
































etabolic  acidosis  (arterial  pH  <  7.3)  is  observed  in  about
%  of  intensive  care  unit  (ICU)  admissions1 and  is  associ-
ted  with  particularly  high  mortality  (up  to  57%).1,2 The
tiology  of  severe  metabolic  acidosis  typically  includes
issue  hypoxemia,  shock,  diabetic  ketoacidosis,  hepatic
nd  renal  failure,  and  intoxications.2 Metabolic  acido-
is  has  numerous  deleterious  consequences  on  various
hysiological  systems,  including  enzyme-/protein  func-
ionality,  tissue  metabolism,  and  increased  production
f  nitric  oxide  leading  to  vasodilatation,3 which  may
urther  amplify  organ  dysfunction.  Furthermore,  acido-
is  is  associated  with  reduced  adrenoceptor  numbers
3n  cellular  surfaces, depression  of  myocardial  func-
ion  including  contractility  and  relaxation,3,4 cardiac






Previous  data  show  that  low  serum  bicarbonate  levels
redict  mortality  at  ICU  admission  in  e.g.  cardiogenic  shock
atients.5,6 Intravenous  sodium  bicarbonate  can  be  applied
o  rapidly  correct  metabolic  acidosis  and  reports  indicate
hat  about  two  thirds  of  North  American  critical  care  spe-
ialists  prescribe  sodium  bicarbonate  for  this  purpose.7
owever,  it  remains  uncertain  whether  metabolic  acido-
is  should  be  corrected  using  sodium  bicarbonate  (or  other
uffers).8,9 Importantly,  there  are  concerns  that  sodium
icarbonate  therapy  could  lead  to  sodium  and/or  fluid  over-
oad,  increased  lactate  and/or  carbon  dioxide  production,
nd/or  decreased  ionized  serum  calcium.10 Thus,  sodium
icarbonate  might  theoretically  worsen  the  outcome  of
ffected  patients.11
Current  evidence  on  whether  sodium  bicarbonate
mpacts  on  mortality  in  the  critically  ill  is  controver-
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As  most  of  the  available  studies  are  performed  in  aci-
otic  patients  with  sepsis13,15 or  hyperlactatemia,12,16 we
hus  embarked  to  perform  a  retrospective  analysis  with  the
rimary  objective  to  investigate  whether  infusion  of  sodium-
icarbonate  impacts  on  all-cause  mortality  in  critically  ill
atients  with  all-cause  metabolic  acidosis  including  but  not
estricted  to  septic  and  lactic  acidosis.
atients and methods
atients
 monocentric  propensity-score  matched  analysis  of  elec-
ronic  patient  charts  was  performed.  Patients  were  treated
t  the  Department  of  Intensive  Care  Medicine,  University
f  Bern,  Switzerland,  between  January  2012  and  December
016.  Patients  were  excluded  when  any  of  the  following  cri-
eria  was  met  I)  refusal  to  provide  general  consent  for  use  of
lectronic  health  care  data  for  patients  treated  after  Jan-
ary  1st  2015  (standardized  general  consent  [GC]  procedure
stablished  in  the  Department  of  Intensive  Care  Medicine),
nd  II)  patients  with  incomplete  basic  datasets  in  regard
o  age,  gender,  Acute  Physiology  and  Chronic  Health  Eval-
ation  (APACHE)  II-Score  at  ICU-admission,  discharge  data
nd/or  ICU  mortality  data.  Routinely  recorded  data  from
lectronic  patient  charts  was  assessed  (Centricity  Critical
are;  General  Electrics,  Helsinki,  Finland).
The  study  was  approved  by  the  local  Ethics  Committee
n  Human  Research  (Kantonale  Ethikkommission,  KEK,  Bern,
r.  2018-01829),  who  waived  the  need  for  individual  written
nformed  consent  due  to  the  GC  procedure  described  above.
atients  were  grouped  for  treatment  with  sodium  bicarbon-
te  8.4%  during  the  ICU  stay  vs.  without  sodium-bicarbonate
nto  sodium  bicarbonate  (SB)  and  control  groups  (noSB).  We
hose  the  sodium  bicarbonate  8.4%  concentration  as  this  is
he  formulation  of  choice  in  our  ICU  to  treat  severe  acidemia
f  necessary.  For  the  preliminary  data  selection,  we  used  the
vailable  basic  data  set  (age,  gender,  and  APACHE  II  scores  at
CU  admission)  to  pair  control  patients  to  sodium  bicarbon-
te  treated  patients  in  a  3:1  ratio  to  gain  a  meaningful  subset
f  ICU  patients  with  comparable  baseline  disease  severity.
rimary  and  secondary  outcomes
rimary  outcome  was  all-cause  mortality  (crude  and
djusted)  at  ICU-discharge  and  all-cause  mortality  at  hos-
ital  discharge  in  patients  with  (non-respiratory)  metabolic
cidosis  (defined  as  pH  ≤  7.3,  pCO2 <  45  mmHg)  treated  with
ersus  without  sodium  bicarbonate  infusion.  Secondary
bjectives  were  excess  mortality  (mortality  beyond  ICU  mor-
ality)  at  30  days,  at  one  year  following  ICU  discharge  and
xcess  mortality  after  more  than  one  year  until  the  last-
ossible  follow-up  (hospital  discharge  until  September  2019)
o  better  differentiate  a  short  term  effect  from  a  hypothet-
cal  long  term  effect.ariables  collected/study  data
ata  was  derived  from  electronic  patient  charts.  Source  data







 (xxxx)  xxx--xxx
nd  BH)  before  extraction.  Inconsistencies  were  discussed
nd  a  consensus  was  sought  between  the  two  examiners.  The
ollowing  routinely  collected  data  were  available:  patient
ge,  diagnostic  and  comorbidity  groups  (APACHE  IV  diag-
ostic  groups),  body  mass  index  (BMI),  APACHE  II  scores,
ime  of  ICU  admission/discharge,  time  of  hospital  admis-
ion/discharge,  cumulative  dose  of  sodium-bicarbonate
eceived,  laboratory  data  at  admission  including  arterial  pH,
rterial  carbon  dioxide  (paCO2),  base  excess  (BE),  bicar-
onate  (HCO3−),  lactate,  sodium,  potassium,  hemoglobin
Hb),  creatinine,  time  on  and  cumulative  dose  of  vasopres-
ors/inotropes  (noradrenaline,  adrenaline,  dobutamine),
otal  volume  of  packed  red  blood  cells  (RBC)  and  fresh  frozen
lasma  (FFP),  need  for  renal  replacement  therapy  (RRT),
ime  on  mechanical  ventilation  (in-  to  extubation),  length  of
tay  (LOS)  in  ICU/hospital,  vital  status  at  ICU-  and  hospital
ischarge  (alive/dead),  time  of  death.
tatistical  analysis
e  explored  the  marginal  univariate  distributions  of  the
reatment  variables  in  the  ‘‘crude’’  data  set  (Suppl.  Fig.  1).
ue  to  asymmetry  in  the  continuous  variables  we  report  the
-values  of  Kolmogorov-Smirnov  test  for  continuous  varia-
les  and  chi-squared  test  for  categorical  variables  (for  the
ull  hypothesis  of  equal  frequencies  between  two  groups).
he  p-values  are  to  be  interpreted  as  measure  of  dissimilar-
ty  (p-values  close  to  0  correspond  to  high  dissimilarity).
A  propensity  score  (PS)  ê(x)  was  estimated  using  logistic
egression  in  which  the  SB  treatment  status  was  regressed
n  pH,  paCO2 and  HCO3−.  Pairs  of  treated  and  untreated
atients  were  matched  on  the  propensity  score  using  a
aliper  of  width  0.3  of  the  standard  deviation  of  the  logit
f  the  propensity  score  (using  the  R  package  ‘‘Matching’’
y  Diamond  and  Sekhon,  2013).  We  considered  mortality
t  ICU  discharge  as  well  as  death  outcomes  at  hospital  dis-
harge,  after  30  days,  at  one  year  and  death  after  more  than
ne  year  (after  hospital  discharge  until  maximum  follow-
p  (the  latter  without  ICU-mortality).  Mortality  occurrences
ere  regressed  on  the  set  of  covariates  with  logit  logistic
egression.  The  covariates  for  the  full  weighted  sample  were
B  treatment  status,  propensity  score,  sex,  age,  BMI  and
PACHE  II  scores.  In  the  matched  sample,  given  that  treated
atients  and  controls  were  paired  with  respect  to  propen-
ity  scores  (as  well  as  pH,  paCO2 and  HCO3−),  the  covariates
et  was  restricted  to  SB  treatment  status,  sex,  age,  BMI  and
PACHE  II.
The  Average  Treatment  effect  in  Treated  (ATT)  is  the
xpected  effect  of  the  treatment  for  individuals  in  the  treat-
ent  group,17 while  the  average  treatment  effect  (ATE)  is
he  expected  effect  of  the  treatment  across  all  individu-
ls  in  the  population.  Randomized  Clinical  Trials  (RCTs)  are
sually  organized  in  such  way  that  ATE  equals  ATT  (unless
xplicitly  specified  exceptions).  Difference  between  ATE
nd  ATT  would  indicate  that  the  treatment  assignment  was
ot  random  or  not  random  enough  in  the  study  consider-
ng  covariates  of  interest.  We  computed  the  ATE  Odds  Ratio
OR)  and  ATT  OR18 with  standard  errors  by  Abadie  and  Imbens
2006)  on  a  matched  sample19; as  well  as  the  ATE  OR  on  the
ull  sample  with  inverse  weighting  by  ATE  weights20 given
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ntreated;  finally  we  provide  an  ATT  OR  on  a  full  sample
ith  inverse  weighting  by  ATT  weights21 given  by  1  for  the
reated  subjects  and  by ê(x)/(1  − ê(x))  for  untreated.
We  estimated  survival  curves  and  relative  survival  effects
ith  Cox  regression  models  by  regressing  survival  on  SB
reatment  status,  sex,  age,  BMI  and  APACHE  II.  Both  anal-
ses  were  done  for  the  maximum  follow-up  as  well  as  for
 20  days  follow-up  as  for  the  majority  of  patients  (97.5%)
he  ICU  stay  was  below  20  days.  In  the  ‘‘crude’’  unmatched
ataset,  we  added  the  propensity  score  to  the  covariates
et.  We  used  a  robust  variance  estimator  to  account  for
he  clustering  within  the  matched  set  and  weighting  in  the
‘crude’’  samples.
esults
 total  of  18,754  admissions  of  ICU  patients  were  screened  in
he  study  interval.  After  removal  of  duplicates  and  patients
ith  incomplete  data  sets,  16,966  data  sets  remained.  Of
hese,  749  patients  received  sodium  bicarbonate  (SB  group)
uring  ICU  stay.  We  performed  a  1:3  pairing  of  patients  with
egard  to  age,  gender  and  APACHE  II  score  at  ICU  admission
o  narrow  further  data  search  on  patients  with  comparable
isease  severity.  For  respective  n  =  2165  patients,  further
ata  collection  was  performed.  While  exploring  the  data,
e  removed  n  =  69  very  extreme  outliers  with  aberrant  val-
es  (eventually  data  entry  mistakes)  in  ICU  length  of  stay  and
ery  high  vasopressor  support  in  addition  to  patients  without
cidosis  (pH  >  7.3,  n  =  1125).  441  (SB)  and  530  (noSB)  patients
emained  in  the  final  ‘‘crude’’  dataset.  A  Consort  flow  chart
s  given  (Fig.  1).
Patient  characteristics  of  this  ‘‘crude’’  data  set  are
iven  in  Table  1.  Median  dose  of  sodium  bicarbonate  8.4%
iven  in  the  SB-group  was  100  ml  (interquartile  range  [IQR]
00--242  ml).  Patients  received  SB  after  a  median  time  of
.14  h  following  ICU  admission  (IQR  14.64  h).  The  SB-group
ad  lower  APACHE  II  scores  than  the  noSB-group  (median
0;  IQR  11  vs.  32;  IQR  19;  p  <  0.001).  Further,  statisti-
ally  significant  differences  were  observed  between  groups
egarding  pH  (SB  median  7.17;  IQR  0.15]  vs.  noSB  7.23;
QR0.09;  p  <  0.01),  arterial  HCO3− (SB  median  12.4  mmol/l;
QR  8.11]  vs.  noSB  17.7  mmol/l;  IQR  5.28;  p  <  0.001)  and
dditional  acidosis-related  indices  (Table  1).  Patients  in  the
B  group  differed  significantly  from  nonSB  patients  in  regard
o  admission  diagnosis  such  as  sepsis,  metabolic  disorders,
ntoxications,  need  for  vasoactives  and  blood  products,  and
eed  for  RRT  (all  p  <  0.05).  ICU  mortality  was  higher  in  the
odium-bicarbonate  group  (SB  46%  vs  noSB  31%;  p  <  .001)
Table  1).  Median  time  to  death  in  non-survivors  was  7.66
ays  (IQR  279.3days)  in  the  noSB-Group  vs.  3.32  days  in  the
B-group  (IQR  37.53days)  (p  <  .001).
The  ORs  for  the  ATT  with  regard  to  (all-cause)  ICU  mor-
ality  and  (all-cause)  in-hospital  excess  mortality  (mortality
eyond  ICU  mortality)  in  the  ‘‘crude’’  dataset  adjusted  for
B  treatment  status,  sex,  age,  BMI  and  APACHE  scores  were
.56  (95%  confidence  interval  [CI]  1.17--2.07;  p  =  .002)  resp.
.67  (95%CI  0.43--1.03;  p  =  .07).  The  ATT  OR  for  excess  mor-
ality  at  30  days,  between  day  31  and  364  and  over  one  year
re  0.52  (95%CI  0.32--0.84;  p  =  .007),  1.31  (95%CI  0.74--2.31;
 =  .357)  and  0.72  (95%CI  0.47--1.09;  p  =  .121)  respectively
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ropensity  score  analysis
e  constructed  the  PS  model  that  fitted  to  971  observations
nd  explained  34%  of  variability  in  treatment  prescription.
hile  dropping  615  observations  (described  in  Suppl.  Table
),  we  achieved  a  sound  matching  between  the  treatment
nd  control  groups  (Suppl.  Fig.  2.).
Using  propensity  scores,  we  obtained  a  dataset  with  348
atients  equally  split  between  the  control  and  sodium  bicar-
onate  groups.  Patient  characteristics  are  given  (Fig.  1,
able  2).  Median  cumulative  dose  of  sodium  bicarbonate
as  100  ml  (IQR  100,  200)  applied  after  a  median  of  8.77  h
ollowing  ICU  admission  (IQR  2.56,  23.51).  ICU-mortality,  in-
ospital  excess  mortality  and  excess  mortality  after  hospital
ischarge  as  well  as  median  time-to-death  did  not  differ  sig-
ificantly  (p  for  all  >.05)  (Table  2).  Median  hospital  LOS  was
onger  in  the  SB  group  than  in  the  noSB  group  (9  days;  IQR
7.2  days  vs.  6  days;  IQR16days;  p  =  .01)
In  the  matched  data  set,  we  observed  no  association  of
odium  bicarbonate  with  ICU-mortality  or  death  outcomes
either  in  the  ATE  OR  nor  in  the  ATT  OR  (Table  3).
As  for  the  majority  of  patients  (97.5%),  ICU  length  of
tay  was  below  20  days,  we  estimated  crude  Kaplan--Meier
urvival  curves  up  to  20  days  (i.e.  if  death  did  not  occur
fter  20  days  from  admission,  we  reported  it  as  no  death
vent  during  20  days).  The  Kaplan--Meier  estimate  of  the
‘crude’’  data  showed  that  the  patients  who  received  the
odium  bicarbonate  treatment  had  considerably  lower  sur-
ival  probability  (log-rank  test:  p  =  .005;  Fig.  2),  while  using
he  matched  data,  there  was  no  significant  difference  (strat-
fied  log-rank  test  p  =  .53).  Applying  the  ATE  and  ATT  weights
n  the  ‘‘crude’’  sample  (n  =  971)  did  not  result  in  a  difference
n  probability  of  survival  (stratified  log-rank  test  p  = .91  and
98,  respectively)  (Fig.  2).  Estimating  Kaplan--Meier  survival
urves  for  the  whole  follow-up  time  showed  no  different
esults  (Suppl.  Fig.  3).
Cox  regression  modeling  did  not  reveal  a  significant
ifference  in  survival  at  20  days  (Hazard  ratio  [HR]  (mul-
ivariable,  matched  sample,  n  =  348:  1.16;  95%CI  0.86--1.56;
 =  .33)  (Table  4).
iscussion
n  this  monocentric  propensity  score  matched  analysis,  we
bserved  no  influence  of  sodium  bicarbonate  infusion  on  ICU-
ortality  in  critically  ill  patients  with  metabolic  acidosis.
In  critically  ill  patients,  it  appears  that  sodium  bicarbon-
te  infusion  is  mostly  prescribed  as  symptomatic  measure
iming  to  influence  effects  of  severe  metabolic  acidosis
e.g.  on  the  cardiovascular  system)  until  a  more  causal
herapy  (e.g.  improvement  of  tissue  oxygenation,  source
ontrol  strategies,  and/or  antibiotics)  becomes  effective.
urrently,  there  is  uncertainty  whether  SB  infusion  would
mpact  on  patient  survival  beneficially  or  whether  it  would
.g.  induce  sodium  and/or  fluid  overload,  increase  paCO2
roduction,  and  would  potentially  be  detrimental.10 Previ-
us  studies  supported  this  assumption  and  showed  that  SB
dministration  in  metabolic  acidosis  may  actually  increase
ortality.16 In  contrast,  the  BICAR-ICU-trial12 and  a  ret-
ospective  study  of  Zhang  et  al.13 showed  no  impact  on
ortality  when  sodium  bicarbonate  was  administered  to
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Figure  1  Flowchart  of  patient  selection.5
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Table  1  Patient  demographics,  ICU  treatment,  and  follow-up  data  of  ‘‘crude’’  patient  population.
Variable  n(all)  =  971  n(noSB)  =  530  n(SB)  =  441  n  avail.  obs.  p
Gender  Female:  318  (33%)  Female:  164  (31%)  Female:  154  (35%)  971  .21
BMI (kg/m2)  26.12  [6]  26.12  [5.95]  26.23  [6.26]  971  .77
Age (years)  67  [17.5]  67  [17]  66  [18]  971  .12
APACHE II  31  [10.5]  32  [19]  30  [11]  971  <.001
DG Cardiovasc.  342  (35%)  191  (36%)  151  (34%)  971  .61
DG Respiratory  176  (18%)  114  (22%)  62  (14%)  971  <.001
DG Gastroint.  107  (11%)  49  (9%)  58  (13%)  971  .07
DG Neurological  80  (8%)  63  (12%)  17  (4%)  971  <.001
DG Trauma  &  TBI 42  (4%) 31  (6%) 11  (2%) 971  .02
DG Metabolic  &  Intox 62  (6%) 16  (3%) 46  (10%) 971  <.001
DG Haemat.  disease 17  (2%) 9  (2%) 8  (2%) 971  1
DG Renal  16  (2%)  8  (2%)  8  (2%)  971  .91
DG Sepsis  99  (10%)  40  (8%)  59  (13%)  971  <.001
apH 7.21  [0.13]  7.23  [0.09]  7.17  [0.15]  971  <.001
aHCO3 (mmol/L)  15.5  [6.4]  17.7  [5.28]  12.4  [8.11]  971  <.001
aLactate (mmol/L)  1  [1]  0.9  [0.6]  1.2  [2.4]  971  <.001
apCO2 (mmHg)  28.7  [8.8]  30.55  [7.28]  26.1  [8]  971  <.001
BE −10.9  [−8]  −8.15  [−6.3]  −14.7  [7.7]  971  <.001
Hc 0.27  [0.07]  0.28  [0.08]  0.26  [0.07]  934  <.001
Na (mmol/L)  134  [6]  134  [6]  134  [6]  957  .8
K (mmolL/)  3.6  [0.7]  3.6  [0.7]  3.6  [0.8]  957  .21
CreaS (mmol/L)  110  [94.5]  101  [88.5]  120  [109]  920  <.001
Adrenaline (y/n)  440  (45%)  193  (36%)  247  (56%)  971  <.001
Adrenaline CD  (g)  3980.35  [9690.6]  1661.96  [5100]  6310.7  [10,871.1]  440  <.001
Noradrenaline  (y/n)  676  (70%)  340  (64%)  336  (76%)  971  <.001
Noradrenaline  CD  (g)  3091.82  [10,659.1]  2133.73  [6632.2]  4614.32  [15,641.4]  676  <.001
Ventilation (y/n)  640  (66%)  372  (70%)  268  (61%)  971  <.001
Blood products  (y/n)  512  (53%)  234  (44%)  278  (63%)  971  <.001
RRT (y/n)  222  (23%)  88  (17%)  134  (30%)  971  <.001
Length of  ICU  stay  (days)  2.57  [4.62]  2.57  [4.26]  2.58  [4.91]  971  .59
Length of  hospital  stay  (days)  8  [15]  7  [15]  8  [16]  937  .14
ICU mortality  366  (38%)  164  (31%)  202  (46%)  971  <.001
In-hospital excess  mortality  103  (11%)  63  (12%)  40  (9%)  971  .19
30d excess  mortality  84  (9%)  54  (10%)  30  (7%)  971  .08
Excess mortality  d31--365  69  (7%)  40  (8%)  29  (7%)  971  .64
Excess mortality  at  last  follow  upa 122  (13%)  74  (14%)  48  (11%)  971  0.18
Time to  death  (days)  5.23  [92.4]  7.66  [279.3]  3.32  [37.53]  722  <.001
Median values [interquartile ranges] or numbers (percentages) are given. ‘p’ refers to Kolmogorov--Smirnov test for continuous variables,
or to chi-squared test for categorical variables (for the null hypothesis of equal categorical frequencies between two groups). Laboratory
data are at admission to ICU. NoSB, non sodium-bicarbonate recipients; SB, sodium-bicarbonate recipients; avail.obs., available observa-
tions; APACHE II, Acute Physiology and Chronic Health Evaluation-II-Score; DG, Diagnosis Group is referring to the APACHE IV-classification
of diagnosis ad admission with a separate sepsis group (all groups include operative and non-operative diagnoses); Cardiovasc., Cardiovas-
cular; Gastroint., Gastrointestinal; Haemat., Hematological; BE, base excess; Hc, hematocrit; Na, sodium; K, potassium; CreaS, serum
creatinine; TBI, traumatic brain injury; NA, noradrenalin; CD, cumulative dose; RRT, renal replacement therapy; ICU, intensive care
unit; d, day; y, yes; n, no.













Last follow up: September 2019. Please note that excess mor
and at last follow up (mortality is excess mortality plus ICU morta
ritically  ill  patients  with  metabolic  acidosis.  In  line  with  the
forementioned  studies,  we  did  not  observe  an  increased
ortality  after  sodium  bicarbonate  treatment.  In  contrast
o  the  BICAR-study12 and  the  study  of  Zhang,13 however,  we
ikely  studied  a  rather  broad  population  of  ICU  patients  with
etabolic  acidosis  as  we  included  not  only  patients  with





 is given for in-hospital mortality and mortality at d30, d31--365
In  addition,  and  in  accordance  with  previous  data,12,13
ur  study  did  not  observe  mortality  benefits  in  patients  with
odium  bicarbonate  infusion.  However,  although  specula-
ive,  e.g.  negative  SB-induced  effects  could  theoretically
e  counterweighted  by  beneficial  effects  such  as  improved
ardiac  contractility  and/or  vascular  responsiveness  to  cat-
cholamine  therapy,3 without  effects  on  the  mortality
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Table  2  Patient  demographics,  ICU  treatment,  and  follow-up  data  of  propensity  score  matched  patient  population  (n  =  348).
Variable n(no  SB)  =  174  n(SB)  =  174  p
Gender  Female:  55  (32%)  Female:  50  (29%)  .64
BMI (kg/m2)  25.5  [6.25]  26.83  [7.91]  .2
Age (years)  68  [16]  68  [17]  .94
APACHE II  32  [8]  28  [11]  <.001
DG Cardiovascular 68  (39%) 55  (32%)  .18
DG Respiratory 18  (10%) 33  (19%) .03
DG Gastrointestinal 27  (16%) 26  (15%) 1
DG Neurological 15  (9%) 10  (6%) .41
DG Trauma  incl.  TBI  9  (5%)  5  (3%)  .41
DG Metabolic  &  Intox  10  (6%)  13  (7%)  .67
DG Hemic  disease  3  (2%)  3  (2%)  1
DG Renal  4  (2%)  2  (1%)  .68
DG Sepsis  15  (9%)  18  (10%)  .71
apH 7.23  [0.08]  7.23  [0.09]  1
aHCO3-- (mmol/L)  15.1  [3.4]  15.25  [3.7]  1
aLactate (mmol/L)  1  [0.8]  1  [1.0]  .45
apCO2 (mmHg)  28  [6.1]  28.1  [6]  .99
BE −11  [−4.1]  −11.25  [−4]  .17
Hc 0.27  [0.07]  0.26  [0.07]  .98
Na (mmol/L)  134  [4.2]  134  [6]  .98
K (mmol/L)  3.6  [0.7]  3.6  [0.8]  .98
CreaS (mmol/L)  118  [84.5]  125  [131]  <.001
Adrenaline (y/n) 76  (44%) 85  (49%) .39
Adrenaline  CD  (g) 2675.07  [11,215.1] 5956.06  [11,098.4] .13
Noradrenaline  (y/n)  109  (63%)  135  (78%)  <.001
Noradrenaline  CD  (g)  2471.82  [6512.9]  3330.52  [13,183.4]  .09
Ventilation (y/n)  126  (72%)  111  (64%)  .11
Blood Products  (y/n)  91  (52%)  111  (64%)  .04
RRT (y/n)  44  (25%)  43  (25%)  1
Length of  ICU  stay  (days)  2.65  [4.2]  2.87  [5.1]  .54
Length of  hospital  stay  (days)  6  [16]  9  [17.2]  .01
ICU mortality  55  (32%)  72  (41%)  .07
InHospital excess  mortality  22  (13%)  18  (10%)  .61
30d excess  mortality  20  (11%)  11  (6%)  .13
Excess mortality  d31--365  12  (7%)  15  (9%)  .69
Excess mortality  at  last  follow  upa 26  (15%)  23  (13%)  .76
Time to  death  (days)  5.22  [274.9]  6.25  [47.3]  .91
Median values [interquartile ranges] or counts (percentages) are given. ‘p’ refers to Kolmogorov--Smirnov test for continuous variables,
or to chi-squared test for categorical variables (for the null hypothesis of equal categorical frequencies between two groups). Laboratory
data are at admission to ICU. DG, Diagnosis Group is referring to the APACHE IV-classification of diagnosis ad admission with a sepa-
rate sepsis group (all groups include operative and non-operative diagnoses); Cardiovasc., Cardiovascular; Gastroint., Gastrointestinal;
Haemat., Hematological; NoSB, non sodium bicarbonate recipients; SB, sodium-bicarbonate recipients; APACHE II, Acute Physiology and
Chronic Health Evaluation II Score; Hc, hematocrit; Na, sodium; K, potassium; CreaS, serum creatinine; TBI, traumatic brain injury; CD,
cumulative dose; RRT, renal replacement therapy; ICU, intensive care unit.















Last follow up: September 2019. Please note that excess mor
and at last follow up (mortality is excess mortality plus ICU morta
ndpoints.  Further,  effects  (whether  beneficial  or  not)  could
heoretically  be  short-  rather  than  long-lived.
Importantly,  about  50%  or  more  patients  who  received
odium  bicarbonate  did  not  have  a  ‘‘severe’’  metabolic
cidosis  with  pH  ≤  7.21 (Tables  1  and  3).  However,  when  com-
ared  to  other  investigations,  our  results  (median  pH  of  7.17
n  ‘‘crude’’  and  7.23  in  matched  groups)  may  be  consid-




 is given for in-hospital mortality and mortality at d30, d31--365
im  et  al.:  mean  pH  7.244  ±  0.168)16;  Zhang  et  al.:  mini-
um  mean  pH  7.16  ±  0.1)13).  Moreover,  the  median  arterial
CO2 in  the  matched  groups  was  28  mmHg.  Therefore,  the
bserved  pH  at  admission  may  be  respiratory  compensated
nd  true  pH  in  fact  considerably  lower.Further,  one  might  assume  that  SB  patients  would  have
ad  a  higher  risk  of  death.  However,  in  our  subset  of  ICU
atients,  SB  treated  patients  had  a  slightly,  but  statistically
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Table  3  Odds  ratios  (OR)  for  treatment  effects  for  mortality  in  the  matched  dataset.
ATE  (matched
sample),  n  =  348
p-Value  ATT  (matched
sample),  n  =  348
p-Value
ICU  mortality  1.08  (0.991,  1.17)  .08  1.09  (0.987,  1.2)  .09
In Hospital  excess  mortality  0.982  (0.924,  1.04)  .55  0.984  (0.92,  1.05)  .62
30d excess  mortality  0.96  (0.91,  1.01)  .13  0.958  (0.903,  1.02)  .16
Excess mortality  d31--365  1.02  (0.968,  1.08)  .44  1  (0.94,  1.06)  .98
Excess mortality  at  last  follow-upa 0.994  (0.935,  1.06)  .82  0.993  (0.928,  1.06)  .83
Reported are the odds ratios (OR) for the treatment effects for mortality at various stages in presence of sodium bicarbonate treatment.
Estimated by logit logistic regressions, regressing mortality outcome on SB treatment status, sex, age, BMI and APACHE.
a Last follow up was in September 2019. ATE, Average Treatment Effect; ATT, Average Treatment effect in Treated. Please note that
excess mortality is given for in-hospital mortality and mortality at d30, d31--365 and at last follow up (mortality is excess mortality plus
ICU mortality).
Figure  2  Kaplan--Meier  survival  curves  (20  days)  obtained  using  different  propensity  score  methods.  In  the  top-left  panel  crude
Kaplan--Meier survival  curves  for  treated  and  untreated  subjects  in  the  ‘‘crude’’  sample  (n  =  971;  log-rank  test:  p  =  0.005).  In  the
top-right panel  Kaplan--Meier  survival  curves  for  treated  and  untreated  subjects  in  the  propensity  score  matched  sample  (n  =  348
stratified log-rank  test  p  =  0.53).  In  the  bottom-left  and  bottom-right  panels  survival  curves  in  the  sample  weighted  using  the  ATE
w ts  (n






eights (n  =  971)  and  the  sample  weighted  using  the  ATT  weigh
nd 0.98).  ATE,  Average  Treatment  Effect;  ATT,  Average  Treatm
ignificant,  lower  baseline  APACHE  II  score,  whereas  ICU
ortality  tended  to  be  increased.  This  stands  in  contrast
o  previous  data13,14 but  may  theoretically  underline  that







 =  971)  are  reported  (adjusted  log-rank  test  with  p-values  0.91
ffect  in  Treated.
A  number  of  important  additional  limitations  of  our  anal-
sis  deserve  discussion.  First,  limitations  arise  from  the
etrospective,  single-center,  and  explorative  design  of  this
tudy  and  all  respective  inherent  limitations  apply  that  are
riven  by  study  design.  In  this  retrospective  study,  even  if
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Table  4  Hazard  ratios  estimated  with  Cox  regressions.













sample  n  =  348)
HR  (multivariable,
full  sample  with  ATE
weights,  n  =  971)
HR  (multivariable,
full  sample  with  ATT






p  =  .005)
1.08
(0.87--1.34,
p  =  .50)
1.16
(0.86--1.56,
p  =  .33)
1.07  (0.93--1.22,
p  =  .35)
1.05  (0.87--1.27,





p <  .001)
1.15
(1.07--1.23,
p  <  .001)
--  1.14  (1.09--1.19,
p  <  .001)
1.18  (1.09--1.28,
p  <  .001)
APACHE II 1.03
(1.02--1.05,
p  <  .001)
1.03
(1.02--1.05,
p  <  .001)
1.03
(1.00--1.05,
p  =  .05)
1.02  (1.01--1.03,
p  <  .001)
1.02  (1.01--1.04,
p  =  .002)







































































A p value < 0.05 was considered statistically significant.
ortality  analyses  were  adjusted  for  typical  potential  con-
ounders,  our  data  may  theoretically  be  subject  to  some
egree  of  unmeasured  confounding.  Additionally,  by  def-
nition,  the  matched  sample  analysis  required  extensive
xclusion  of  patients  of  the  overall  sample,  which  may  per
e  introduce  (e.g.  selection)  bias.  Moreover,  this  may  point
o  heterogeneity  of  the  total  cohort  and  may  be  one  rea-
on  why  respective  patients  were  particularly  challenging
o  match.  By  deliberately  curtailing  our  ICU  data  set  to
 subset  of  patients  and  by  removing  some  outliers  that
imed  for  a  comparable  subset  of  ICU  patients,  it  may  the-
retically  be  possible  that  some  degree  of  selection  bias
as  introduced.  Second,  we  only  considered  intravenous
odium  bicarbonate  formulations  of  8.4%  for  analysis  and
ight  have  missed  other  preparations,  including  e.g.  chronic
ral  bicarbonate  use  in  few  patients  with  chronic  kidney  dis-
ase.  Third,  mortality  may  not  be  an  optimal  endpoint  to
xamine  effects  of  an  early  single  intervention  in  a  criti-
ally  ill  population,  which  may  also  underline  our  interest
n  early  outcomes  of  our  cohort  (i.e.  20  days  of  ICU  stay).  It
ppears  that  endpoints  related  to  therapy-induced  effects
e.g.  increase  in  pH)  might  be  particular  interesting  in  subse-
uent  investigations.  Fourth,  our  retrospective  study  design
ade  it  impossible  to  identify  the  medical  reason  for  the
independent  treating)  physician  to  prescribe  sodium  bicar-
onate  and  for  the  timing  of  the  prescription.  We  can  thus
ot  exclude  with  certainty  that  SB  was  also  given  for  aeti-
logies  of  metabolic  acidosis  with  a  better  prognosis  (e.g.
iabetic  ketoacidosis,  intoxications)  or  other  reasons  than
or  metabolic  acidosis  only,  e.g.  in  cases  of  additional  rhab-
omyolysis.  Although  the  current  analysis  may  be  one  of
he  largest  investigations  available,  it  appeared  that  the
ample  size  was  too  limited  to  conclude  back  on  effects
f  SB  dose  and/or  exact  timing  as  well  as  to  conclude  on
ubgroups  of  critically  ill  patients  (e.g.  acute  kidney  injury
AKI]  or  sepsis  patients,  patient’s  post-surgical  interven-
ions).  Thus,  the  presented  analysis  may  theoretically  be
‘underpowered’’.  Fifth,  we  did  not  evaluate  other  impor-
ant  covariates  such  as  interventions  during  the  ICU  stay
e.g.  emergency  hemodialysis)  as  well  as  respective  urgency





ncluding  fluid  balance.  Sixth,  the  presented  mortality  data
eflects  all-cause  mortality  and  we  are  unable  to  conclude
ack  on  specific  acidosis  and/or  treatment-related  adverse
ffects  nor  on  different  causes  of  death.  Seventh,  as  our
etrospective  analysis  made  it  impossible  to  conclude  back
n  acid  base  analysis  after  sodium  bicarbonate  infusion  we
annot  describe  any  influence  of  sodium  bicarbonate  on  the
H  and  the  bicarbonate  level  after  treatment.  Moreover,
e  refrained  from  estimating  dose-effects  of  the  sodium
icarbonate  given.
onclusion
n  this  propensity  score  matched  analysis,  intravenous
dministration  of  sodium  bicarbonate  did  not  appear  to
ffect  on  mortality  in  ICU  patients  with  metabolic  acido-
is.  Additional  prospective  controlled  clinical  investigations
eem  required  to  further  determine  potential  effects  of
odium  bicarbonate  infusion  in  subgroups  of  patients  with
etabolic  acidosis,  including  potential  high-risk  groups,
uch  as  critically  ill  patients  with  AKI.
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